The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients protocol for a randomised controlled trial
Standard
The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients protocol for a randomised controlled trial. / Sommerer, Claudia; Schaier, Matthias; Morath, Christian; Schwenger, Vedat; Rauch, Geraldine; Giese, Thomas; Zeier, Martin.
in: TRIALS, Jahrgang 15, 13.12.2014, S. 489.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients protocol for a randomised controlled trial
AU - Sommerer, Claudia
AU - Schaier, Matthias
AU - Morath, Christian
AU - Schwenger, Vedat
AU - Rauch, Geraldine
AU - Giese, Thomas
AU - Zeier, Martin
PY - 2014/12/13
Y1 - 2014/12/13
N2 - BACKGROUND: Adequate monitoring tools are required to optimise the immunosuppressive therapy of an individual patient. Particularly, in calcineurin inhibitors, as critical dose drugs with a narrow therapeutic range, the optimal monitoring strategies are discussed in terms of safety and efficacy. Nevertheless, no pharmacokinetic monitoring markers reflect the biological activity of the drug. A new quantitative analysis of gene expression was employed to directly measure the functional effects of calcineurin inhibition: the transcriptional activities of the nuclear factor of activated T-cell (NFAT)-regulated genes in the peripheral blood.METHODS/DESIGN: The CIS study is a randomised prospective controlled trial, comparing a ciclosporin A (CsA)-based immunosuppressive regimen monitored by CsA trough levels to a CsA-based immunosuppressive regimen monitored by residual NFAT-regulated gene expression. Pulse wave velocity as an accepted surrogate marker of the cardiovascular risk is assessed in both study groups. Our hypothesis is that an individualised CsA therapy monitored by residual NFAT-regulated gene expression results in a significantly lower cardiovascular risk compared to CsA therapy monitored by CsA trough levels.DISCUSSION: There is a lack of evidence in individualising standard immunosuppression in renal allograft recipients. The CIS study will consider the feasibility of individualised ciclosporin A immunosuppression by pharmacodynamic monitoring and evaluate the opportunity to reduce cardiovascular risk while maintaining sufficient immunosuppression.TRIAL REGISTRATION: EudraCT identifier 2011-003547-21, registration date 18 July 2011https://www.clinicaltrialsregister.eu.
AB - BACKGROUND: Adequate monitoring tools are required to optimise the immunosuppressive therapy of an individual patient. Particularly, in calcineurin inhibitors, as critical dose drugs with a narrow therapeutic range, the optimal monitoring strategies are discussed in terms of safety and efficacy. Nevertheless, no pharmacokinetic monitoring markers reflect the biological activity of the drug. A new quantitative analysis of gene expression was employed to directly measure the functional effects of calcineurin inhibition: the transcriptional activities of the nuclear factor of activated T-cell (NFAT)-regulated genes in the peripheral blood.METHODS/DESIGN: The CIS study is a randomised prospective controlled trial, comparing a ciclosporin A (CsA)-based immunosuppressive regimen monitored by CsA trough levels to a CsA-based immunosuppressive regimen monitored by residual NFAT-regulated gene expression. Pulse wave velocity as an accepted surrogate marker of the cardiovascular risk is assessed in both study groups. Our hypothesis is that an individualised CsA therapy monitored by residual NFAT-regulated gene expression results in a significantly lower cardiovascular risk compared to CsA therapy monitored by CsA trough levels.DISCUSSION: There is a lack of evidence in individualising standard immunosuppression in renal allograft recipients. The CIS study will consider the feasibility of individualised ciclosporin A immunosuppression by pharmacodynamic monitoring and evaluate the opportunity to reduce cardiovascular risk while maintaining sufficient immunosuppression.TRIAL REGISTRATION: EudraCT identifier 2011-003547-21, registration date 18 July 2011https://www.clinicaltrialsregister.eu.
KW - Calcineurin Inhibitors
KW - Clinical Protocols
KW - Cyclosporine
KW - Drug Monitoring
KW - Gene Expression Regulation
KW - Germany
KW - Graft Rejection
KW - Graft Survival
KW - Humans
KW - Immunosuppressive Agents
KW - Kidney Transplantation
KW - Monitoring, Immunologic
KW - NFATC Transcription Factors
KW - Predictive Value of Tests
KW - Prospective Studies
KW - Pulse Wave Analysis
KW - Research Design
KW - Time Factors
KW - Treatment Outcome
KW - Comparative Study
KW - Journal Article
KW - Randomized Controlled Trial
KW - Research Support, Non-U.S. Gov't
U2 - 10.1186/1745-6215-15-489
DO - 10.1186/1745-6215-15-489
M3 - SCORING: Journal article
C2 - 25494823
VL - 15
SP - 489
JO - TRIALS
JF - TRIALS
SN - 1745-6215
ER -